Search
IC41
go.drugbank.com/drugs/DB05776InvestigationalIt is being devloped by Intercell AG for the treatment of hepatitis C. … The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the synthetic adjuvant poly-L-arginine.
Hydroxypropyl cellulose
go.drugbank.com/drugs/DB00840ApprovedIt is used to treat syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis
Metreleptin
go.drugbank.com/drugs/DB09046ApprovedInvestigational[L41315] Metreleptin was approved by Health Canada in January 2024 for the same patient population, in addition to patients with partial lipodystrophy.[L49901] … [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized
Pork collagen
go.drugbank.com/drugs/DB14100ApprovedThe surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.
Mixtures: P3 Rg, P3 RgInavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational[A264563] Newer PI3K inhibitors, like inavolisib, seek to mitigate this attenuation. … [A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme InducersEdoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawnIt was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … [A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113]
Synonyms: 2'-Deoxy-5-ethyluridine, 5-Ethyl-2'-deoxyuridineDifenoxin
go.drugbank.com/drugs/DB01501ApprovedIllicitIt is approved by the FDA to treat acute and chronic diarrhea. … It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide
CIGB 300
go.drugbank.com/drugs/DB16464InvestigationalCIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma
Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalRecently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK … Fostamatinib has also been granted orphan drug status by the FDA [L2644].
Categories: Phosphodiesterase 5 Inhibitors, Cytochrome P-450 SubstratesSusoctocog alfa
go.drugbank.com/drugs/DB11606ApprovedInvestigationalIt is the first recombinant porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and safety by measuring factor VIII activity levels in addition to clinical … The recombinant porcine sequence allows less susceptibility to inactivation by circulating human factor VIII antibodies.